https://www.fiercebiotech.com/biotech/glycomine-grabs-115m-series-c-fund-phase-2-journey-rare-genetic-disorder-drug
Glycomine's $115M series C to fund genetic disorder ph. 2 plans
Apr 16, 2025 - Glycomine has bagged a $115 million series C to continue the progress of its lead candidate through phase 2 development for a rare genetic disorder.
series c
https://www.glycomine.com/
Replacement Therapies for Rare Diseases| PMM2-CDG | Glycomine
Apr 2, 2026 - We are developing a PMM2-CDG substrate replacement therapy. GLM101 is a mannose-1 phosphate treatment.
rare diseasesreplacementtherapiescdg
https://convention.bio.org/participating-companies/glycomine-inc
Glycomine, Inc. - BIO International Convention 2026
bio international conventioninc